LATEST PRESS RELEASES
MAY 8, 2024 / REGULATORY
IRLAB publishes interim report for the period January-March 2024
Gothenburg, Sweden, May 8, 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company’s interim report for the period January-March 2024, has been published.
Read More >
MAY 7, 2024 / REGULATORY
IRLAB Enters a Development Collaboration for IRL757 as a Novel Treatment for Apathy
Read More >
MAY 6, 2024
IRLAB has received approval from the Swedish Medical Products Agency to conduct a Phase I study of the drug candidate IRL757
Read More >
EVENT CALENDAR
FINANCIAL CALENDAR
NEXT
week 18 (April 29-May 3)
Annual report
FOLLOWING
May 8, 2024
Interim report January-March 2024